Wells Fargo’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-6,800
Closed -$3.08M 7472
2025
Q4
$3.08M Buy
+6,800
New +$2.93M ﹤0.01% 3089
2025
Q1
Sell
-3,600
Closed -$1.45M 7290
2024
Q4
$1.45M Buy
+3,600
New +$1.67M ﹤0.01% 3438
2022
Q2
Sell
-73,000
Closed -$19.1M 7578
2022
Q1
$19.1M Buy
73,000
+60,500
+484% +$14.4M ﹤0.01% 1339
2021
Q4
$2.75M Buy
+12,500
New +$2.43M ﹤0.01% 3182
2021
Q2
Sell
-17,500
Closed -$3.76M 7499
2021
Q1
$3.76M Buy
+17,500
New +$3.84M ﹤0.01% 3112

Other funds holding VRTX

Wells Fargo's VRTX Position: Q2 2026 in Review

Wells Fargo increased its Vertex Pharmaceuticals (VRTX) stake by 0.61% in Q2 2026, buying an estimated $2.01M and bringing the position to 749,528 shares worth $372M. The position accounts for 0.06% of the portfolio, ranked #269.

Wells Fargo first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. The position peaked at $443M in Q2 2020. 1,756 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Wells Fargo held 749,528 shares of Vertex Pharmaceuticals worth $372M as of Q2 2026.
  • Wells Fargo bought 4,533 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.01M.
  • Vertex Pharmaceuticals made up 0.06% of Wells Fargo's portfolio in Q2 2026, its #269 holding.
  • Wells Fargo first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Wells Fargo's Vertex Pharmaceuticals position peaked at $443M in Q2 2020.
  • 1,756 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.